COP vs SPRY · P/E 19, rev $58.94B vs rev $89.1M
ConocoPhillips (COP) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
COP currently screens at market cap $135.49B and trailing P/E 18.8. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the COP and SPRY stock pages for the full models.
Not investment advice.